Crinetics Pharmaceuticals CRNX 深 沪
交易中 08-24 11:48:23 美东时间
84.785
+0.095
+0.11%
华盛通- 最 高84.80
- 今 开84.72
- 成交量 28.39万股
- 最 低 84.71
- 昨 收 84.69
- 总市值 89.95亿
- 52周最高 84.80
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 31.00
- 委 比 19.46%
- 总股本 1.06亿
- 历史最高 84.80
- 量 比 0.24
- 振 幅 0.11%
- 历史最低 10.63
- 每 手 1
- 风险率 15.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crinetics nears shareholder vote on Vertex merger
An update from Crinetics Pharmaceuticals ( ($CRNX) ) is now available. On July ...
08-14 21:21
Top 3 Health Care Stocks That May Implode In August
As of Aug. 12, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices ...
08-12 20:58
High-flyer healthcare stocks: Ten names with strong momentum, weak valuations
Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price velocity against fu...
08-10 20:49
财报速睇 | Crinetics Pharmaceuticals 2026财年Q2营收0.25亿美元，同比增长2400.0%；归母净利润亏损1.21亿美元，同比亏损扩大4.3%
华盛资讯8月4日讯，Crinetics Pharmaceuticals公布2026财年Q2业绩，公司Q2营收0.25亿美元，同比增长2400.0%，归母净利润亏损1.21亿美元，同比亏损扩大4.3%。
08-04 05:54
财报速睇 | Crinetics Pharmaceuticals 2026财年Q2营收0.25亿美元，同比增长2336.3%；归母净利润亏损1.21亿美元，同比亏损扩大4.5%
华盛资讯8月4日讯，Crinetics Pharmaceuticals公布2026财年Q2业绩，公司Q2营收0.25亿美元，同比增长2336.3%，归母净利润亏损1.21亿美元，同比亏损扩大4.5%。
08-04 05:42
Crinetics Pharmaceuticals Q2 EPS $(1.14) Beats $(1.24) Estimate, Sales $25.118M Beat $14.840M Estimate
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.24) by 8.06 percent. This is a 7.32 percent increase over losses of $(1.23) per share from the same period last year. The company reported quarterly sales of $25.11...
08-04 04:13
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--ACA, CRNX, LEG, and LPSN
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...
08-04 03:21
AbCellera inks drug discovery deal with Vertex Pharma
AbCellera (ABCL) on Wednesday announced a collaboration with Vertex Pharmaceuticals (VRTX) to discover and conduct early research into certain T-cell engagers targeting conditions such as autoimmune d...
07-29 22:24
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
UBS Downgrades Crinetics Pharmaceuticals to Neutral, Raises Price Target to $85
UBS analyst Ashwani Verma downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Buy to Neutral and raises the price target from $55 to $85.
07-28 20:27
